While most studies of tumor and blood suggest that changes in CD8+ T cells correlate with ICB outcomes, other T cell populations in the MPE, such as CD4+ helper T cells, could also be predictive of ICB outcomes. This evidence concerns the gene CD4 and neoplasm.